164 filings
10-K
2023 FY
MNPR
Monopar Therapeutics Inc
Annual report
28 Mar 24
7:01am
8-K
MNPR
Monopar Therapeutics Inc
28 Mar 24
Monopar Reports Fourth Quarter and Full-Year 2023
7:00am
8-K
MNPR
Monopar Therapeutics Inc
7 Mar 24
Regulation FD Disclosure
8:30am
8-K
MNPR
Monopar Therapeutics Inc
5 Mar 24
Monopar Announces Positive Preclinical Therapeutic Isotope Data
7:00am
8-K
MNPR
Monopar Therapeutics Inc
28 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:45pm
8-K
z7iskwo4gwv4fo662s
27 Feb 24
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
6:59am
8-K
349t67pgp9xehbx
22 Feb 24
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
7:00am
8-K
umj7rdy8jp3r35
20 Feb 24
Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical
8:00am
8-K
uwtihng1
9 Nov 23
Monopar Therapeutics Reports Third Quarter 2023
7:00am
8-K
huw6vjvty9vy4
1 Nov 23
Monopar Presents Data Showing Tumor Reduction Benefit of
7:00am
8-K
hx1fn
30 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:16pm
8-K
s6qgtj68q38xel1di
10 Aug 23
Monopar Therapeutics Reports Second Quarter 2023
7:00am
8-K
vw73chg7mm
8 Aug 23
Monopar Provides Encouraging Camsirubicin Clinical Data Update
7:00am
8-K
r79 4s1xbws12qc3
11 Jul 23
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
7:00am
8-K
jv7ea1esm0562
28 Jun 23
Submission of Matters to a Vote of Security Holders
4:13pm
8-K
bfu5e36b
1 Jun 23
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
7:01am
8-K
urr0 v060snpnmip7kj
11 May 23
Monopar Therapeutics Reports First Quarter 2023
7:03am